237 related articles for article (PubMed ID: 17889852)
21. The rat Digit Abduction Score (DAS) assay: a physiological model for assessing botulinum neurotoxin-induced skeletal muscle paralysis.
Broide RS; Rubino J; Nicholson GS; Ardila MC; Brown MS; Aoki KR; Francis J
Toxicon; 2013 Sep; 71():18-24. PubMed ID: 23707612
[TBL] [Abstract][Full Text] [Related]
22. Syntaxin and 25-kDa synaptosomal-associated protein: differential effects of botulinum neurotoxins C1 and A on neuronal survival.
Williamson LC; Neale EA
J Neurosci Res; 1998 Jun; 52(5):569-83. PubMed ID: 9632313
[TBL] [Abstract][Full Text] [Related]
23. Selection and characterization of a human monoclonal neutralizing antibody for Clostridium Botulinum neurotoxin serotype B.
Zhou H; Zhou B; Pellett S; Johnson EA; Janda KD
Bioorg Med Chem Lett; 2009 Feb; 19(3):662-4. PubMed ID: 19112017
[TBL] [Abstract][Full Text] [Related]
24. Immunological characterization of the subunits of type A botulinum neurotoxin and different components of its associated proteins.
Kukreja R; Chang TW; Cai S; Lindo P; Riding S; Zhou Y; Ravichandran E; Singh BR
Toxicon; 2009 May; 53(6):616-24. PubMed ID: 19673075
[TBL] [Abstract][Full Text] [Related]
25. Rapid Microfluidic Assay for the Detection of Botulinum Neurotoxin in Animal Sera.
Babrak L; Lin A; Stanker LH; McGarvey J; Hnasko R
Toxins (Basel); 2016 Jan; 8(1):. PubMed ID: 26742073
[TBL] [Abstract][Full Text] [Related]
26. An evaluation of neutralizing antibody induction during treatment of glabellar lines with a new US formulation of botulinum neurotoxin type A.
Lawrence I; Moy R
Aesthet Surg J; 2009 Nov; 29(6 Suppl):S66-71. PubMed ID: 19945007
[TBL] [Abstract][Full Text] [Related]
27. Type A botulinum neurotoxin complex proteins differentially modulate host response of neuronal cells.
Wang L; Sun Y; Yang W; Lindo P; Singh BR
Toxicon; 2014 May; 82():52-60. PubMed ID: 24560879
[TBL] [Abstract][Full Text] [Related]
28. Uptake of botulinum neurotoxin into cultured neurons.
Keller JE; Cai F; Neale EA
Biochemistry; 2004 Jan; 43(2):526-32. PubMed ID: 14717608
[TBL] [Abstract][Full Text] [Related]
29. Avian eyelid assay, a new diagnostic method for detecting botulinum neurotoxin serotypes A, B and E.
Wang J; Gao S; Zhang Q; Kang L; Liu Y
Toxicon; 2007 Jun; 49(7):1019-25. PubMed ID: 17367833
[TBL] [Abstract][Full Text] [Related]
30. Comparative membrane channel size and activity of botulinum neurotoxins A and E.
Parikh S; Singh BR
Protein J; 2007 Jan; 26(1):19-28. PubMed ID: 17216364
[TBL] [Abstract][Full Text] [Related]
31. Development of Germline-Humanized Antibodies Neutralizing Botulinum Neurotoxin A and B.
Miethe S; Mazuet C; Liu Y; Tierney R; Rasetti-Escargueil C; Avril A; Frenzel A; Thullier P; Pelat T; Urbain R; Fontayne A; Sesardic D; Hust M; Popoff MR
PLoS One; 2016; 11(8):e0161446. PubMed ID: 27560688
[TBL] [Abstract][Full Text] [Related]
32. Individual and bivalent vaccines against botulinum neurotoxin serotypes A and B using DNA-based Semliki Forest virus vectors.
Yu Y; Yu J; Li N; Wang S; Yu W; Sun Z
Vaccine; 2009 Oct; 27(44):6148-53. PubMed ID: 19712769
[TBL] [Abstract][Full Text] [Related]
33. Exchanging the minimal cell binding fragments of tetanus neurotoxin in botulinum neurotoxin A and B impacts their toxicity at the neuromuscular junction and central neurons.
Höltje M; Schulze S; Strotmeier J; Mahrhold S; Richter K; Binz T; Bigalke H; Ahnert-Hilger G; Rummel A
Toxicon; 2013 Dec; 75():108-21. PubMed ID: 23817019
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the primary rat spinal cord cell (RSC) assay and the mouse bioassay for botulinum neurotoxin type A potency determination.
Pellett S; Tepp WH; Toth SI; Johnson EA
J Pharmacol Toxicol Methods; 2010; 61(3):304-10. PubMed ID: 20100585
[TBL] [Abstract][Full Text] [Related]
35. Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display.
Levy R; Forsyth CM; LaPorte SL; Geren IN; Smith LA; Marks JD
J Mol Biol; 2007 Jan; 365(1):196-210. PubMed ID: 17059824
[TBL] [Abstract][Full Text] [Related]
36. Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization.
Smith TJ; Lou J; Geren IN; Forsyth CM; Tsai R; Laporte SL; Tepp WH; Bradshaw M; Johnson EA; Smith LA; Marks JD
Infect Immun; 2005 Sep; 73(9):5450-7. PubMed ID: 16113261
[TBL] [Abstract][Full Text] [Related]
37. Neutralizing antibodies of botulinum neurotoxin serotype A screened from a fully synthetic human antibody phage display library.
Yu R; Wang S; Yu YZ; Du WS; Yang F; Yu WY; Sun ZW
J Biomol Screen; 2009 Sep; 14(8):991-8. PubMed ID: 19726786
[TBL] [Abstract][Full Text] [Related]
38. Novel application of an in vitro technique to the detection and quantification of botulinum neurotoxin antibodies.
Hall YH; Chaddock JA; Moulsdale HJ; Kirby ER; Alexander FC; Marks JD; Foster KA
J Immunol Methods; 2004 May; 288(1-2):55-60. PubMed ID: 15183085
[TBL] [Abstract][Full Text] [Related]
39. Recommended Immunological Strategies to Screen for Botulinum Neurotoxin-Containing Samples.
Simon S; Fiebig U; Liu Y; Tierney R; Dano J; Worbs S; Endermann T; Nevers MC; Volland H; Sesardic D; Dorner MB
Toxins (Basel); 2015 Nov; 7(12):5011-34. PubMed ID: 26703727
[TBL] [Abstract][Full Text] [Related]
40. Development of a Highly Sensitive Cell-Based Assay for Detecting Botulinum Neurotoxin Type A through Neural Culture Media Optimization.
Hong WS; Pezzi HM; Schuster AR; Berry SM; Sung KE; Beebe DJ
J Biomol Screen; 2016 Jan; 21(1):65-73. PubMed ID: 26420788
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
